Skip to main content

Table 2 Overview of patient’s data

From: 18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?

Parameter

Number (%)

Patients, total

36

 Age, years, median

60

 Age, years, range

44–76

 Sex, male

20 (55.5%)

 Sex, female

16 (44.5%)

MM subtype

 IgG Kappa/Lambda

12 (33.3%)/7 (19.4%)

 IgA Kappa/Lambda

3 (8.3%)/2 (5.6%)

 IgM Lambda

1 (2.8%)

 Light chain only, Kappa

5 (13.9%)

 Light chain only, Lambda

3 (8.3%)

 Non-secretory

3 (8.3%)

High-dose therapies with SCTs

 One autologous SCT

17 (47.2%)

 Two autologous SCT

12 (33.3%)

 Three autologous SCT

1 (2.8%)

 Allogeneic SCT (following autologous)

6 (16.7%) [5(13.9%)]

Therapy lines before current progress

 First line

13 (36.1%)

 Second line

9 (25%)

 Third line

8 (22.2%)

 Fourth line

4 (11.1%)

 Fifth line

2 (5.6%)

 Median

2

ISS2 stage at current progress

 I

19 (52.8%)

 II

13 (36.1%)

 III

4 (11.1%)

Cytogenetics on FISH

 High-eisk

6 (16.6%)

 Non-high-risk

15 (41.7%)

 Cytogenetics not available

15 (41.7%)

LDH

 Elevated (> 250 U/l)

20 (55.5%)

 Normal (≤ 250 U/l)

16 (44.5%)

Best response after last therapy line

 CR

10 (27.7%)

 vgPR

5 (13.9%)

 PR

19 (52.8%)

 SD

2 (5.6%)

  1. SCT stem cell transplantation, ISS international staging system, FISH fluorescence in situ hybridization, CR complete remission, vgPR very good partial remission, PR partial remission, SD stable disease